# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises the price target fro...
2024 Financial Guidance We are increasing our annual revenue guidance to the range of $182 million to $186 million. We are als...
Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve inju...
Raymond James analyst Jayson Bedford initiates coverage on Axogen (NASDAQ:AXGN) with a Outperform rating and announces Price...
Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve inju...